

## HR 4278

To direct the Comptroller General of the United States to conduct a study on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers, and for other purposes.

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Jun 30, 2021

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Jul 1, 2021)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/4278>

### Sponsor

**Name:** Rep. Murphy, Gregory [R-NC-3]

**Party:** Republican • **State:** NC • **Chamber:** House

### Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Harshbarger, Diana [R-TN-1]	R · TN		Jun 30, 2021

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jul 1, 2021

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

No related bills are listed.

### Summary (as of Jun 30, 2021)

This bill requires the Government Accountability Office to study and report on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers.

### Actions Timeline

- **Jul 1, 2021:** Referred to the Subcommittee on Health.
- **Jun 30, 2021:** Introduced in House
- **Jun 30, 2021:** Referred to the House Committee on Energy and Commerce.